Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

[1]  A. Mokdad,et al.  Preventive cardiologyAbstractBrief Communication: The Prevalence of High Intake of Vitamin E From the Use of Supplements Among U.S. Adults , 2005 .

[2]  J. Manson,et al.  Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer: The Women’s Health Study: A Randomized Controlled Trial , 2005, JAMA.

[3]  Michael M Lieber,et al.  Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). , 2005, Journal of the National Cancer Institute.

[4]  P. Boffetta,et al.  Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons , 1997, Cancer Causes & Control.

[5]  Catherine A McCarty,et al.  Vitamin E supplementation and cataract: randomized controlled trial. , 2004, Ophthalmology.

[6]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[7]  Ping-Yu Liu,et al.  Factorial design considerations. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Schouten,et al.  Effect of daily vitamin E and multivitamin-mineral supplementation on acute respiratory tract infections in elderly persons: a randomized controlled trial. , 2002, JAMA.

[9]  H. Taylor,et al.  Vitamin E supplementation and macular degeneration: randomised controlled trial , 2002, BMJ : British Medical Journal.

[10]  B. Turnbull,et al.  Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[11]  Kukin Ml.  The Heart Outcomes Prevention Evaluation Study. , 2001, Current cardiology reports.

[12]  Jennifer I. Lim,et al.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. , 2001, Archives of ophthalmology.

[13]  R. Wiklund,et al.  Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients , 2000 .

[14]  I. Thompson,et al.  SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design , 2000, Prostate Cancer and Prostatic Diseases.

[15]  C. Bouchard,et al.  Associations between the leptin receptor gene and adiposity in middle-aged Caucasian males from the HERITAGE family study. , 2000, The Journal of clinical endocrinology and metabolism.

[16]  E. Rimm,et al.  Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[17]  M. Spitz,et al.  Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. , 1999, Carcinogenesis.

[18]  C. Wadelius,et al.  Prostate cancer associated with CYP17 genotype. , 1999, Pharmacogenetics.

[19]  Jack A. Taylor,et al.  Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). , 1999, Carcinogenesis.

[20]  R. Santella.  Immunological methods for detection of carcinogen-DNA damage in humans. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[21]  P. Vineis.  Metabolic Polymorphisms and Susceptibility to Cancer , 1999 .

[22]  A. Hanlon,et al.  Racial differences in insulin-like growth factor binding protein-3 in men at increased risk of prostate cancer. , 1999, Urology.

[23]  P. Lønning,et al.  CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1. , 1999, Cancer research.

[24]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[25]  E. Lander,et al.  Androgen Metabolism and Prostate Cancer: Establishing a Model of Genetic Susceptibility , 1998, European Urology.

[26]  U. Vogel,et al.  Polymorphisms in the DNA repair gene XPD: correlations with risk and age at onset of basal cell carcinoma. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[27]  J. Lear,et al.  Glutathione S-transferase polymorphisms: influence on susceptibility to cancer. , 1998, Chemico-biological interactions.

[28]  C. Mantzoros,et al.  Leptin in relation to prostate cancer and benign prostatic hyperplasia , 1998 .

[29]  I. M. Jones,et al.  Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. , 1998, Cancer research.

[30]  Meir J. Stampfer,et al.  Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study , 1998 .

[31]  J. French,et al.  Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. , 1997, Cancer research.

[32]  L. Harries,et al.  Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. , 1997, Carcinogenesis.

[33]  G. Paolisso,et al.  Serum levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in healthy centenarians: relationship with plasma leptin and lipid concentrations, insulin action, and cognitive function. , 1997, The Journal of clinical endocrinology and metabolism.

[34]  S. Brichard,et al.  Insulin and insulin-like growth factor 1 antagonize the stimulation of ob gene expression by dexamethasone in cultured rat adipose tissue. , 1997, The Biochemical journal.

[35]  Y. Song,et al.  Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone , 1997, International Journal of Obesity.

[36]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[37]  D. Forman,et al.  Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. , 1997, Carcinogenesis.

[38]  F. Lönnqvist,et al.  Relationship between circulating leptin and peripheral fat distribution in obese subjects , 1997, International Journal of Obesity.

[39]  S. O’Rahilly,et al.  Depot- and Sex-Specific Differences in Human Leptin mRNA Expression: Implications for the Control of Regional Fat Distribution , 1997, Diabetes.

[40]  D. Kiel,et al.  Association of Insulin‐Like Growth Factor‐I with Body Composition, Weight History, and Past Health Behaviors in the Very Old: The Framingham Heart Study , 1997, Journal of the American Geriatrics Society.

[41]  D. Magoffin,et al.  Direct Intraovarian Effects of Leptin: Impairment of the Synergistic Action of Insulin-Like Growth Factor-I on Follicle-Stimulating Hormone-Dependent Estradiol-17β Production by Rat Ovarian Granulosa Cells. , 1997, Endocrinology.

[42]  C. Mantzoros,et al.  Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. , 1997, British Journal of Cancer.

[43]  M R Cullen,et al.  Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. , 1996, Journal of the National Cancer Institute.

[44]  S. Klein,et al.  Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates. , 1996, The Journal of clinical endocrinology and metabolism.

[45]  E. Ferrannini,et al.  Acute insulin administration does not affect plasma leptin levels in lean or obese subjects , 1996, European journal of clinical investigation.

[46]  S. Haffner,et al.  Leptin concentrations in relation to overall adiposity and regional body fat distribution in Mexican Americans. , 1996, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[47]  Igor Sartori,et al.  A Clinical Trial of Antioxidant Vitamins to Prevent Colorectal Adenoma. , 1996 .

[48]  P. Vineis,et al.  Genetic metabolic polymorphisms and the risk of cancer: a review of the literature. , 1996, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[49]  F. Kadlubar,et al.  Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogen-DNA adduct levels and human cancer susceptibility. , 1996, Progress in clinical and biological research.

[50]  E. Bowman,et al.  Human Lung Carcinogen—DNA Adduct Levels Mediated by Genetic Polymorphisms In Vivo , 1995 .

[51]  J. Little,et al.  Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. , 1994, Human molecular genetics.

[52]  H. Yamamoto,et al.  Body composition assessed by bioelectrical impedance analysis (BIA) and the correlation with plasma insulin-like growth factor I (IGF-I) in normal Japanese subjects and patients with acromegaly and GH deficiency. , 1994, Endocrine journal.

[53]  D. Albanes,et al.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.

[54]  J. French,et al.  The growth hormone: insulin-like growth factor 1 axis is a mediator of diet restriction-induced inhibition of mononuclear cell leukemia in Fischer rats. , 1993, Cancer research.

[55]  A. C. Beach,et al.  Human biomonitoring and the 32P-postlabeling assay. , 1992, Carcinogenesis.

[56]  D. Leroith,et al.  Insulin-like Growth Factors in Health and Disease , 1992 .

[57]  W. Miller,et al.  Tissue-specific, cyclic adenosine 3',5'-monophosphate-induced, and phorbol ester-repressed transcription from the human P450c17 promoter in mouse cells. , 1990, Molecular endocrinology.

[58]  S. Tannenbaum,et al.  Protein adducts in the molecular dosimetry of chemical carcinogens. , 1990, Carcinogenesis.

[59]  A. Penn,et al.  Arteriosclerotic plaque development is 'promoted' by polynuclear aromatic hydrocarbons. , 1988, Carcinogenesis.

[60]  Robert Tjian,et al.  Promoter-specific activation of RNA polymerase II transcription by Sp1 , 1986 .

[61]  Leon Speroff,et al.  Clinical gynecologic endocrinology and infertility , 1983 .